CPHI Online Report - Pharma Market Trends 2021
Pharma Market Trends 2021
Twelve pharma market trends we anticipate across 2021 for the drug development, manufacturing and outsourcing sectors.
2020 has been one of the most turbulent years in recent history and has cast a shroud of uncertainty over the future. While pharmaceutical companies have proved instrumental in responding to the pandemic through innovation, collaboration and manufacturing expertise, COVID-19 has also raised fresh challenges for the industry to overcome.
In this trend report, we explore the key opportunities, disruptors and dynamics which the industry will face throughout 2021.
Pharma’s response to the pandemic in terms of vaccines development and distribution of treatments has grabbed the majority of the headlines but the major issues facing the industry are by no means exclusively coronavirus related.
In interviews with key industry experts, this report identifies key trends that we anticipate throughout 2021, as pharmaceutical manufacturing and outsourcing continue to respond not only to the challenges that the ongoing global crisis has presented, but also to evolving obstacles and hurdles that are typical in such a highly-regulated sector.
Key pharma market trends for 2021:
- Supply chain resilience to take precedence over reshoring of active pharmaceutical ingredient manufacturing
- Pandemic accelerates digital transformation of API sourcing and trading
- Suppy chain security and patient centricity focus
- Cure vs. treatment model shifts CDMO contracts from volume to value
- A gradual breakthrough for continuous manufacturing of APIs
- COVID-19 vaccines to take central stage
- Vaccine distribution and roll-out
- Industry fight against antimicrobial resistance to gain prominence
- Enablers of precision medicine: next-generation sequencing
- Continuing consolidation in the pharma contract services sector
- Emerging pharma markets will be key to expansion of pharma and biopharma capabilities
- Rise in biosimilar applications due to patent expiries
Click the link at the bottom of this page to download the complete CPHI Pharma 2021 Trends Report
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance